{"id":"W4387598444","doi":"10.1161/jaha.123.030385","title":"Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors","year":2023,"lang":"en","type":"article","venue":"Journal of the American Heart Association","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"American Regent; Amgen Canada; Bristol-Myers Squibb Canada; Duke Clinical Research Institute; Novo Nordisk; Verily Life Sciences; Medicines Company; Boston Scientific Corporation; Eli Lilly and Company; Bristol-Myers Squibb; CSL Behring; AstraZeneca; National Heart, Lung, and Blood Institute; Pfizer; Amgen; Cytokinetics; Intercept Pharmaceuticals; American Heart Association; Regeneron Pharmaceuticals; U.S. Department of Veterans Affairs","keywords":"Prasugrel; Medicine; Aspirin; Clopidogrel; P2Y12; Discontinuation; Internal medicine; Hazard ratio; Clinical endpoint; Dosing; Stroke (engine); Myocardial infarction; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004472465,0.0004847118,0.002416142,0.0004442116,0.0002932448,0.00104104,0.000457518,0.0007046259,0.001764331],"category_scores_gemma":[0.008945967,0.0002450567,0.002140012,0.0007862021,0.0004561093,0.0004346529,0.0004502321,0.001417488,0.0001188883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004136094,"about_ca_system_score_gemma":0.0008306452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005611783,"about_ca_topic_score_gemma":0.0007441818,"domain_scores_codex":[0.9955445,0.002950858,0.0003667203,0.000363495,0.0005457581,0.0002286214],"domain_scores_gemma":[0.9933669,0.003416641,0.002249615,0.0002307918,0.0002513672,0.0004846052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4543086,0.005283304,0.302777,0.006770617,0.02607198,0.0004121808,0.0003201755,0.002905699,0.004229641,0.001250605,0.005850497,0.1898197],"study_design_scores_gemma":[0.1379796,0.08290521,0.7363411,0.0008531564,0.01862373,0.000894793,0.0001979271,0.007173588,0.003112659,0.00396549,0.007837961,0.0001146907],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9662017,0.02717417,0.001275329,0.001826518,0.0002810733,0.0003374461,0.0006832596,0.00003894674,0.002181601],"genre_scores_gemma":[0.9942847,0.003298506,0.0008392865,0.0004617526,0.0004996969,0.0001720865,0.0003009927,0.000005791278,0.0001372064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004472465,"threshold_uncertainty_score":0.02365291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0110967373534121,"score_gpt":0.2463242723756879,"score_spread":0.2352275350222758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}